Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149914 | 0.90 | GAA (0.86) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL4572221 | 0.89 | GAA (0.78) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL4569533 | 0.89 | GAA (0.83) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL11707330 | 0.89 | GAA (0.74) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL76483 | 0.88 | GAA (0.81) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL29061201 | 0.88 | GAA (0.73) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL1149604 | 0.88 | GAA (0.81) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL7243396 | 0.88 | GAA (0.72) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL39122 | 0.87 | GAA (0.77) | GAAKMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL7244694 | 0.86 | GAA (0.79) | GAAKMT2AMEN1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143324-B2 | antioxidants with hindered phenol functionality perform better in curing of polybenzocyclobutene materials in air without undue degradation of key properties | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110115108-A1 | PHOTOCHROMIC COATING EXHIBITING IMPROVED PERFORMANCE AND REDUCED YELLOWNESS | ESSILOR INTERNATIONAL (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20090275673-A1 | Benzocyclobutene based polymer formulations and methods for processing such formulations in oxidative environments | DOW GLOBAL TECHNOLOGIES LLC | 2009-11-05 | — | — | US | disclosed |
| US-7572325-B2 | Ink carriers, phase change inks including same and methods for making same | XEROX CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080193496-A1 | Antimicrobial And Antiviral Polymeric Master Batch, Processes For Producing Polymeric Material Therefrom And Products Produced Therefrom | THE CUPRON CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080193496-A1 | Antimicrobial And Antiviral Polymeric Master Batch, Processes For Producing Polymeric Material Therefrom And Products Produced Therefrom | THE CUPRON CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070119338-A1 | Ink carriers, phase change inks including same and methods for making same | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193496-A1 | Antimicrobial And Antiviral Polymeric Master Batch, Processes For Producing Polymeric Material Therefrom And Products Produced Therefrom | PICALM, POLM, ZC3HAV1 | GAA 156/4885KMT2A 2802/4885MEN1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.